Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries

  • Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing
  • By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries
  • Cybin filed the PCT application to provide broad international patent protection of key intellectual property

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent coverage in 153 countries (https://ibn.fm/Of5wi). 

“Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific team, have produced Cybin’s first PCT (Patent Cooperation Treaty) filing,” said Cybin CEO Doug Drysdale. “As we progress our R&D and clinical programs, we expect to continue to create and develop innovative therapeutics with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects.”

By filing a single international application with the Patent Cooperation Treaty (“PCT”), Cybin can simultaneously seek protection for its proprietary drug treatments in a large number of countries (https://ibn.fm/zTFMK). In addition, the PCT assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent-granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.

Cybin filed the PCT application to provide broad international patent protection of key intellectual property in support of the company’s strategic objectives. Those objectives include the company’s three-pillar drug development strategy: creating a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen. 

Specifically, the company is working on four drug programs: CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamines designed for treatment of alcohol-use disorder and other therapy-resistant psychiatric disorders; and CYB005, a phenethylamine-targeting psychiatry and neurology treatment. 

Psychedelic therapies are being seriously considered as a novel treatment option for a variety of mental health issues. For decades, psychedelics have been largely ignored because both federal and state laws prohibited the substances. However, a growing body of research is showing evidence of both the efficacy and safety of psychedelic use, and public opinion about the drugs is changing. While psychedelics may feel like a new industry, they actually boast a long history of use within indigenous cultures that stretches back centuries. A paradigm shift has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, and Cybin is leading the way.

Cybin is confident that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050